Researchers explain the mechanisms beyond glucocorticoid resistance in infant MLLr B-ALL leukemia

Published Date: 07 Aug 2024

B-ALL is the most common pediatric cancer and, over the years and thanks to a very effective treatment based on glucocorticoids, its 5-year survival rates have reached 85% and beyond. However, there is a B-ALL subtype, commonly ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot